Dalma Seboek Kinter

622 total citations · 1 hit paper
20 papers, 408 citations indexed

About

Dalma Seboek Kinter is a scholar working on Experimental and Cognitive Psychology, Cognitive Neuroscience and Endocrine and Autonomic Systems. According to data from OpenAlex, Dalma Seboek Kinter has authored 20 papers receiving a total of 408 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Experimental and Cognitive Psychology, 13 papers in Cognitive Neuroscience and 6 papers in Endocrine and Autonomic Systems. Recurrent topics in Dalma Seboek Kinter's work include Sleep and related disorders (15 papers), Sleep and Wakefulness Research (13 papers) and Circadian rhythm and melatonin (6 papers). Dalma Seboek Kinter is often cited by papers focused on Sleep and related disorders (15 papers), Sleep and Wakefulness Research (13 papers) and Circadian rhythm and melatonin (6 papers). Dalma Seboek Kinter collaborates with scholars based in Switzerland, United States and Germany. Dalma Seboek Kinter's co-authors include Scott Pain, David Mayleben, Ingo Fietze, Gary Zammit, Yves Dauvilliers, Claudio L. Bassetti, Emmanuel Mignot, Damien Léger, Thomas Roth and Jan Hedner and has published in prestigious journals such as Annals of Neurology, The Lancet Neurology and SLEEP.

In The Last Decade

Dalma Seboek Kinter

19 papers receiving 389 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials

2022 136 citations Emmanuel Mignot, David Mayleben et al. The Lancet Neurology profile →

Peers

Countries citing papers authored by Dalma Seboek Kinter

Since Specialization

Citations

This map shows the geographic impact of Dalma Seboek Kinter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dalma Seboek Kinter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dalma Seboek Kinter more than expected).

Fields of papers citing papers by Dalma Seboek Kinter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dalma Seboek Kinter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dalma Seboek Kinter. The network helps show where Dalma Seboek Kinter may publish in the future.

Co-authorship network of co-authors of Dalma Seboek Kinter

This figure shows the co-authorship network connecting the top 25 collaborators of Dalma Seboek Kinter. A scholar is included among the top collaborators of Dalma Seboek Kinter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dalma Seboek Kinter. Dalma Seboek Kinter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Meaningful Within-Patient Change in Subjective Total Sleep Time in Patients with Insomnia Disorder: An Analysis of the Sleep Diary Questionnaire Using Data from Open-Label and Phase III Clinical Trials 2024 ·Pharmaceutical Medicine ·(unknown), Ariane K. Kawata, Leah Kleinman, Dalma Seboek Kinter, Bruno Flamion	6
2	Summary of Research: Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) 2023 ·Advances in Therapy ·Stacie Hudgens, (unknown), Louise Newton, Dalma Seboek Kinter, Heike Beneš	1
3	Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem 2023 ·CNS Drugs ·(unknown), Thomas E. Scammell, (unknown), Dalma Seboek Kinter, Alexandre Datta, Gary Zammit, Yves Dauvilliers	14
4	Meaningful Within-Patient Change on the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ): Analysis of Phase III Clinical Trial Data of Daridorexant 2023 ·Pharmaceutical Medicine ·(unknown), Ariane K. Kawata, Leah Kleinman, Dalma Seboek Kinter	6
5	Comparison of sleep microarchitecture in screen failure subjects with insomnia complaints and randomized subjects from two phase 3 studies on insomnia disorder 2023 ·European Psychiatry ·(unknown), Yves Dauvilliers, Thomas E. Scammell, Ina Djonlagic, Alexandre Datta, Gary Zammit, Dalma Seboek Kinter, (unknown), Jacob Donoghue	0
6	Efficacy and Safety of Daridorexant in Older and Younger Adults with Insomnia Disorder: A Secondary Analysis of a Randomised Placebo-Controlled Trial 2022 ·Drugs & Aging ·Ingo Fietze, Claudio L. Bassetti, David Mayleben, Scott Pain, Dalma Seboek Kinter, W. Vaughn McCall	34
7	Safety and efficacy of daridorexant in patients with insomnia disorder: results from two multicentre, randomised, double-blind, placebo-controlled, phase 3 trials breakdown → 2022 ·The Lancet Neurology ·Emmanuel Mignot, David Mayleben, Ingo Fietze, Damien Léger, Gary Zammit, Claudio L. Bassetti, Scott Pain, Dalma Seboek Kinter, Thomas Roth	136
8	Long-Term Safety and Tolerability of Daridorexant in Patients with Insomnia Disorder 2022 ·CNS Drugs ·Dieter Kunz, Yves Dauvilliers, Heike Beneš, Diego García‐Borreguero, Giuseppe Plazzi, Dalma Seboek Kinter, (unknown), (unknown), (unknown), Stephen Thein	52
9	Long-term safety and efficacy of daridorexant in patients with insomnia disorder 2022 ·Sleep Medicine ·Dieter Kunz, Heike Beneš, (unknown), Yves Dauvilliers, Giuseppe Plazzi, (unknown), (unknown), (unknown), Dalma Seboek Kinter, (unknown)	3
10	Preferences of patients for benefits and risks of insomnia medications using data elicited during two phase III clinical trials 2022 ·SLEEP ·Sebastian Heidenreich, Melissa Ross, Gin Nie Chua, Dalma Seboek Kinter, (unknown)	7
11	0455 The Insomnia Daytime Symptoms and Impacts Questionnaire: An Analysis of Clinically Meaningful Change Using Phase 3 Clinical Trial Data 2022 ·SLEEP ·(unknown), Ariane K. Kawata, Leah Kleinman, Dalma Seboek Kinter	1
12	Effects of daridorexant on sleep and daytime functioning in older adults with insomnia 2022 ·American Journal of Geriatric Psychiatry ·Ingo Fietze, Claudio L. Bassetti, David Mayleben, Alberto Gimona, Scott Pain, W. Vaughn McCall, Dalma Seboek Kinter	3
13	348 Absence of Withdrawal Symptoms and Rebound Insomnia Upon Discontinuation of Daridorexant in Patients with Insomnia 2021 ·SLEEP ·Damien Léger, Ingo Fietze, Scott Pain, Dalma Seboek Kinter, Bruno Flamion, Emmanuel Mignot	4
14	347 Daridorexant is Safe and Improves Both Sleep and Daytime Functioning in Elderly Patients with Insomnia 2021 ·SLEEP ·Ingo Fietze, Claudio L. Bassetti, David Mayleben, Alberto Gimona, Scott Pain, Dalma Seboek Kinter	3
15	344 Daridorexant Improves Total Sleep Time (TST) in Insomnia Patients Without Altering the Proportion of Sleep Stages 2021 ·SLEEP ·Gary Zammit, David Mayleben, Ingo Fietze, Scott Pain, Dalma Seboek Kinter, Alberto Gimona, Yves Dauvilliers	1
16	Daridorexant, a New Dual Orexin Receptor Antagonist to Treat Insomnia Disorder 2020 ·Annals of Neurology ·Yves Dauvilliers, Gary Zammit, Ingo Fietze, David Mayleben, Dalma Seboek Kinter, Scott Pain, Jan Hedner	103
17	Development and Validation of the Insomnia Daytime Symptoms and Impacts Questionnaire (IDSIQ) 2020 ·Patient ·Stacie Hudgens, (unknown), Louise Newton, Dalma Seboek Kinter, Heike Beneš	28
18	0521 Daridorexant (ACT-541468), A Dual Orexin Receptor Antagonist for the Treatment of Insomnia Disorder: Double Blind, Randomized, Phase 3 Studies for Efficacy and Safety in Adult and Elderly Patients 2020 ·SLEEP ·Gary Zammit, Dalma Seboek Kinter, Claudio L. Bassetti, Damien Léger, (unknown), Scott Pain, (unknown)	4
19	0375 A Novel Dual Orexin Receptor Antagonist (ACT-541468) to Treat Insomnia: A Randomized, Double-Blind, Placebo-Controlled, Active-Reference Phase 2 Study 2019 ·SLEEP ·Yves Dauvilliers, Gary Zammit, Ingo Fietze, David Mayleben, Dalma Seboek Kinter, Scott Pain, Jan Hedner	1
20	0407 ACT-541468, A Dual Orexin Receptor Antagonist, For The Treatment Of Insomnia Disorder: A Randomized, Double-Blind, Placebo-Controlled, 5-Period, 5-Treatment Crossover Dose-Response Phase 2 Study In The Elderly 2019 ·SLEEP ·Gary Zammit, Yves Dauvilliers, Scott Pain, Dalma Seboek Kinter, Dieter Kunz	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact